Older Eli Lilly's drug fails Alzheimer's prevention trial

Eli Lilly's drug solanezumab failed to slow cognitive decline in Alzheimer's patients. However, two other Alzheimer's drugs, donanemab and remternetug, are in late-stage development.

March 10, 2023 . 9:37 PM

1 min read

Eli Lilly's drug solanezumab failed to slow cognitive decline in patients treated before they showed symptoms.
The drug was designed to target only soluble forms of amyloid beta, a toxic protein that accumulates in the brains of people with Alzheimer's.
The U.S. drugmaker is in late-stage development with two other Alzheimer's drugs, donanemab and remternetug, that specifically target deposited amyloid and have been shown to clear plaque in treated patients.
Lilly expects to announce results from a Phase III trial of donanemab for early Alzheimer's before the end of June.
The company is conducting a 3,300-patient trial of donanemab in asymptomatic Alzheimer's patients.